Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 17:1–16. doi: 10.1080/07391102.2020.1847688

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Informa UK Limited, trading as Taylor & Francis Group

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 10. — A-C: Molecular Modelling and docking studies of antiviral with pol/RdRp protein of COVID-19: Representative 3 D structure of complex docked target protein molecule (POL/RdRp) with antiviral drugs A1) Protein + Adefovir, A2) Protein + Amantadine, A3) Protein + Oseltamivir, A4) Protein + Ribavirin, A5) Protein + Zanamivir (A1-A5). Representative bonding interaction(s) between drug molecules and target protein receptor B1) Protein + Adefovir, B2) Protein + Amantadine, B3) Protein + Oseltamivir, B4) Protein + Ribavirin, B5) Protein + Zanamivir (B1-B5). Representation of 2 D complex structure of antiviral drugs and target protein presenting different types of bonds interacting with number of amino acid residues C1) Protein + Adefovir, C2) Protein + Amantadine, C3) Protein + Oseltamivir, C4) Protein + Ribavirin, C5) Protein + Zanamivir (C1-C5).